BLUE WHALE NEWS, September 12 (Reporter Tu Jun) Following the patent infringement lawsuit filed by AbbVie in June last year regarding its core product, the BTK inhibitor Beyue Ze (zebutinib capsules), recently reported that last Friday, pharmaceutical giant AbbVie sued BeiGene again. The former sued BeiGene State in the US federal court in Chicago, accusing it of stealing trade secrets to develop competitive anti-cancer treatments after hiring a former senior AbbVie scientist.
It is reported that the above project includes BGB-16673, a compound independently discovered by BeiGene researchers through years of innovative research.
On August 27, BeiGene announced that the US FDA granted BGB-16673 fast-track status to treat adult patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two previous lines of treatment (including BTK inhibitors and BCL2 inhibitors). BGB-16673 is an oral, BTK-targeted chimeric degradation activating compound (CDAC) under development.
BeiGene told Blue Whale Finance that it will resolutely defend the accusations initiated by AbbVie. BeiGene denies this allegation and will vigorously defend its intellectual property rights against the lawsuit.
“We believe the lawsuit is intended to hinder the development process of BGB-16673, which is currently the fastest progressing BTK degradant in clinical development. BGB-16673 BeiGene applied for a patent for BGB-16673 a few years before AbbVie first applied for a BTK degrading agent patent.” According to the BeiGe Shenzhou side.
Up to now, more than 300 patients from 15 countries and regions have been treated in the BGB-16673 global clinical development program.
BeiGene said that the BGB-16673 development project will not be interrupted by this lawsuit, and that the drug has the potential to become an important treatment plan for patients whose disease progresses after using BTK inhibitors and has limited options.
Affected by the news, today (September 12), BeiGene's A shares fell 10.61% to 144.01 yuan/share, while Hong Kong stocks fell 5.44% to HK$118.3 per share.